Adage Capital Partners Gp, L.L.C. Aldeyra Therapeutics, Inc. Transaction History

Adage Capital Partners Gp, L.L.C.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2020 May 15, 2020	SELL	$1.62 - $6.4 $1.62 Million - $6.4 Million	-1,000,000 Closed	0 $0
Q4 2019 Feb 14, 2020	SELL	$4.73 - $7.98 $1.98 Million - $3.34 Million	-418,822 Reduced 29.52%	1,000,000 $5.81 Million
Q3 2019 Nov 14, 2019	BUY	$4.41 - $6.12 $1.1 Million - $1.53 Million	250,000 Added 21.39%	1,418,822 $7.48 Million
Q2 2019 Aug 14, 2019	BUY	$6.0 - $9.0 $300,000 - $450,000	50,000 Added 4.47%	1,168,822 $7.01 Million
Q1 2019 May 15, 2019	BUY	$7.14 - $9.85 $4.1 Million - $5.65 Million	573,822 Added 105.29%	1,118,822 $10.1 Million
Q4 2018 Feb 14, 2019	BUY	$7.26 - $13.29 $1.12 Million - $2.05 Million	154,000 Added 39.39%	545,000 $4.52 Million
Q3 2018 Nov 14, 2018	SELL	$6.8 - $14.35 $2.44 Million - $5.15 Million	-359,000 Reduced 47.87%	391,000 $5.4 Million
Q1 2018 May 15, 2018	BUY	$6.55 - $8.9 $373,350 - $507,300	57,000 Added 8.23%	750,000 $5.63 Million
Q4 2017 Feb 14, 2018	SELL	$5.7 - $7.75 $324,900 - $441,750	-57,000 Reduced 7.6%	693,000 $4.71 Million
Q3 2017 Nov 14, 2017	BUY	$3.9 - $10.8 $2.93 Million - $8.1 Million	750,000	750,000 $5.4 Million

117

36.4M

196K

142K

Ticker ALDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,323,100
Market Cap $280M
Description
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...

Get notified when there are updates to the investment portfolio of Adage Capital Partners Gp, L.L.C., based on Form 13F filings with the SEC.

Stay updated on Adage Capital Partners Gp, L.L.C. with notifications on news.